Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc) Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2. jaimeuss_admin 6 בSeptember 2018 Research 0 Comments Continue Reading